Thromboembolic events are an important cause of death in critically ill patients with COVID-19, and platelet-mediated immune thrombosis within the plasma of COVID-19 patients can be reversed by blocking FCGR2A-Syk pathway signaling on platelets [47]. Here, FCGR2A is linked to COVID-19.